Showing results (21-30 of 59) with videos related to
Sort By:
Pageof 6
Oncoimmunology|September 19, 2017
MEK inhibition and immune responses in advanced melanomaReinhard Dummer, Egle Ramelyte, Sabrina Schindler, et al.Journal for Immunotherapy of Cancer|July 5, 2024
Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroidsElias Burri, Joanna Mangana, Phil F Cheng, et al.Current Oncology Reports|September 26, 2018
The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the GlobeFlorentia Dimitriou, Regina Krattinger, Egle Ramelyte, et al.Cancers|September 9, 2022
The Prognostic Value of a Single, Randomly Timed Circulating Tumor DNA Measurement in Patients with Metastatic MelanomaAurelio Boerlin, Elisa Bellini, Patrick Turko, et al.STAR Protocols|June 21, 2021
Collection and preprocessing of fine needle aspirate patient samples for single cell profiling and data analysisAizhan Tastanova, Egle Ramelyte, Zsolt Balázs, et al.Genes|July 2, 2021
Clinicopathological and Genomic Profiles of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma Identify Overlapping Signatures with a High Mutational BurdenMelike Ak, Abdullah Kahraman, Fabian M Arnold, et al.Melanoma Research|May 31, 2018
Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysisEsther M Häfliger, Egle Ramelyte, Joanna Mangana, et al.Cancers|August 12, 2023
Clock-like Mutation Signature May Be Prognostic for Worse Survival Than Signatures of UV Damage in Cutaneous MelanomaFabienne Fröhlich, Egle Ramelyte, Patrick Turko, et al.Expert Opinion on Pharmacotherapy|June 3, 2024
Advances in the pharmacological management of cutaneous T-cell lymphomaGabriele Roccuzzo, Andrea Roggo, Egle Ramelyte, et al.Current Oncology (Toronto, Ont.)|April 27, 2026
Re-Exposure of a PD-1 Inhibitor After Previous Immune-Related Adverse EventsJana Burghaus-Zhang, Carsten Schulz, Egle Ramelyte, et al.Pageof 6